Skip to content

Denali Therapeutics Inc. DNLI Available for sale investments

Available for sale investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Biogen logo
BiogenBIIB
BridgeBio Pharma logo
BridgeBio PharmaBBIO
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s available for sale investments?
Denali Therapeutics Inc. (DNLI) reported available for sale investments of $663.84M in Q1 2026.
How has Denali Therapeutics Inc.'s available for sale investments changed year-over-year?
Denali Therapeutics Inc.'s available for sale investments decreased by 33.4% year-over-year, from $996.82M to $663.84M.
What is the long-term trend for Denali Therapeutics Inc.'s available for sale investments?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s available for sale investments has grown at a -5.2% compound annual growth rate (CAGR), from $995.25M to $760.88M.